Combination therapy with CDK4/6 and mTOR inhibitors could also enable the use of lower doses, thus diminishing adverse effects and toxicity in patients, as neutropenia, leukopenia, thrombocytopenia, anemia, fatigue or diarrhea. This evidence concerns the gene CDK4 and Decreased total leukocyte count.